异常凝血酶原在肝细胞癌诊疗中的应用进展

Progress on protein induced by vitamin K absence or antagonist-Ⅱin the diagnosis and therapy of hepatocellular carcinoma

异常凝血酶原即维生素K缺乏或拮抗剂-Ⅱ诱导的蛋白质(protein induced by vitamin K absence or antagonist-Ⅱ,PIVKA-Ⅱ),目前主要用于肝细胞癌的补充诊断。但越来越多的研究发现,PIVKA-Ⅱ在联合其他血清学指标进行高特异度、高敏感度的诊断、治疗前的疗效评估及治疗后的预后评价等方面均具有一定价值,其水平的变化可以为肝移植术、肝切除术时机的选择及微血管侵犯提供新的依据。本文对PIVKA-Ⅱ在肝细胞癌诊疗中应用的研究进展进行综述。

Protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ)is mainly used for the complementary diagnosis of hepatocellular carcinoma,but now more and more studies have found that PIVKA-Ⅱis valuable in combination with other serological indices for highly specific and sensitive diagnosis,pre-treatment efficacy assessment and post-treatment prognosis evaluation,and its level changes can provide a new basis for choice of surgery timing of liver transplantation and hepatectomy and for microvascular invasion.This article will review and discuss the role of PIVKA-Ⅱin the above diagnosis and treatment,aiming to provide more comprehensive theoretical support for the function of PIVKA-Ⅱin hepatocellular carcinoma.